Global Diabetic Foot Ulcer Biologics Market Size & Outlook

The global diabetic foot ulcer biologics market size was estimated at USD 2,006.1 million in 2024 and is projected to reach USD 3,109.7 million by 2030, growing at a CAGR of 7.6% from 2025 to 2030.
Revenue, 2024 (US$M)
$2,006.1
Forecast, 2030 (US$M)
$3,109.7
CAGR, 2025 - 2030
7.6%
Report Coverage
Worldwide

Global diabetic foot ulcer biologics market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Global diabetic foot ulcer biologics market highlights

  • The global diabetic foot ulcer biologics market generated a revenue of USD 2,006.1 million in 2024 and is expected to reach USD 3,109.7 million by 2030.
  • The market is expected to grow at a CAGR (2025 - 2030) of 7.6% by 2030.
  • In terms of segment, skin substitutes accounted for a revenue of USD 1,083.6 million in 2024.
  • Tissue-Engineered Products is the most lucrative product segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2024.
  • Country-wise, Japan is expected to register the highest CAGR from 2025 to 2030.

Global data book summary

Market revenue in 2024USD 2,006.1 million
Market revenue in 2030USD 3,109.7 million
Growth rate7.6% (CAGR from 2025 to 2030)
Largest segmentSkin substitutes
Fastest growing segmentTissue-Engineered Products
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSkin Substitutes, Growth Factors, Tissue-Engineered Products

Other key industry trends

  • In terms of revenue, the North America accounted for 40.0% of the global diabetic foot ulcer biologics market in 2024.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
  • By country, Japan is the fastest growing regional market and is projected to reach USD 143.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Diabetic Foot Ulcer Biologics Market Companies

Name Profile # Employees HQ Website
Gunze View profile 5001-10000 Osaka, Osaka, Japan, Asia https://www.gunze.co.jp/
Stedical Scientific View profile - Carlsbad, California, United States, North America https://www.stedical.com/
ConvaTec Inc. View profile - - -
Tissue Regenix View profile 51-100 York, York, United Kingdom, Europe http://www.tissueregenix.com
BioTissue View profile 1-10 Genève, Geneve, Switzerland, Europe http://www.biotissue.ch
Organogenesis Holdings Inc Class A View profile 862 85 Dan Road, Canton, MA, United States, 02021 https://www.organogenesis.com
MiMedx Group Inc View profile 895 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062 https://www.mimedx.com
Smith & Nephew PLC View profile 18452 Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, United Kingdom, WD18 8YE https://www.smith-nephew.com
Coloplast A/S ADR View profile 15930 Holtedam 1-3, Humlebaek, Denmark, DK-3050 https://www.coloplast.com
Integra Lifesciences Holdings Corp View profile 3946 1100 Campus Road, Princeton, NJ, United States, 08540 https://www.integralife.com
Zimmer Biomet Holdings Inc View profile 18000 345 East Main Street, Warsaw, IN, United States, 46580 https://www.zimmerbiomet.com

Global diabetic foot ulcer biologics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to diabetic foot ulcer biologics market will help companies and investors design strategic landscapes.


Skin substitutes was the largest segment with a revenue share of 54.02% in 2024. Horizon Databook has segmented the Global diabetic foot ulcer biologics market based on skin substitutes, growth factors, tissue-engineered products covering the revenue growth of each sub-segment from 2018 to 2030.


  • Global Diabetic Foot Ulcer Biologics Product Outlook (Revenue, USD Million, 2018-2030)
    • Skin Substitutes
      • Biological
      • Synthetic
      • Bio-Synthetic
    • Growth Factors
    • Tissue-Engineered Products
  • Global Diabetic Foot Ulcer Biologics Indication Outlook (Revenue, USD Million, 2018-2030)
    • Neuro-ischemic Ulcers
    • Neuropathic Diabetic Foot Ulcer
    • Ischemic Diabetic Foot Ulcer
  • Global Diabetic Foot Ulcer Biologics End Use Outlook (Revenue, USD Million, 2018-2030)
    • Hospitals
    • Clinics
    • Ambulatory Surgical Centers (ASCs)
    • Long-Term Care Settings
    • Others

Reasons to subscribe to Global diabetic foot ulcer biologics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global diabetic foot ulcer biologics market databook

  • Our clientele includes a mix of diabetic foot ulcer biologics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global diabetic foot ulcer biologics market , including forecasts for subscribers. This global databook contains high-level insights into Global diabetic foot ulcer biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global diabetic foot ulcer biologics market size, by regions, 2018-2030 (US$M)

Top 10 countries: Diabetic foot ulcer biologics market size, 2024 (US$M)

Global diabetic foot ulcer biologics market share, by product, 2024 & 2030 (%, US$M)

Diabetic foot ulcer biologics market: Opportunity assessment by country

Global diabetic foot ulcer biologics market, by region, 2024 (US$M)

Global diabetic foot ulcer biologics market size, by regions, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online